Huahai Pharmaceutical Gains FDA Approval for Generic Fingolimod
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received Abbreviated New...
Novartis
Shanghai Pharma’s CD20 Antibody Advances to Primary Nephropathy Trial After NMPA Approval
China’s Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products...
Novartis Partners with Beijing’s Changping District to Expand Drug Development
Swiss pharma giant Novartis (NYSE: NVS) has partnered with Beijing’s Changping district government to expand...
Novartis to Spin Off Sandoz, Focus on Innovative Drugs
Swiss drugmaker Novartis announced plans to spin off its generic and biosimilar unit, Sandoz, to...
Novartis Aims for China to Be Second – Largest Market by 2024
Dan Brindle, head of Novartis AG’s (NYSE: NVS) China operations, recently spoke with Xinhua news...
Sunshine Guojian’s SSGJ-608 Hits Primary Endpoint in Psoriasis Study
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...
Transcenta Appoints Dr. Caroline Germa as Global Drug Development Chief
China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced the appointment of Dr. Caroline Germa as...
MabPharm’s CMAB015 Biosimilar Receives NMPA Approval for Clinical Study
Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received...
Novartis Q2 Results Show 5% Growth, Led by Entresto and Cosentyx
Swiss pharma giant Novartis (NYSE: NVS) reported a 5% year-on-year (YOY) revenue increase in constant...
Novartis’ Aimovig Launches in China via GBA Early Access Scheme for Migraine Treatment
Swiss pharma giant Novartis’ (NYSE: NVS) migraine therapy Aimovig (erenumab) was administered for the first...
Hrain Biotech and Novartis Receive Breakthrough Therapy Designations for CAR-T and Zolgensma
The Center for Drug Evaluation (CDE) website indicates that Hrain Biotechnology Co., Ltd’s BCMA –...
Novartis Cuts Back on US Development of BeiGene’s PD-1 Inhibitor Tislelizumab
Novartis AG (NYSE: NVS), BeiGene’s partner, revealed in its Q3 2022 earnings report that it...
Novartis’ Tislelizumab Faces FDA Hurdle in First-Line NSCLC Monotherapy
Novartis disclosed during its Q2 2022 earnings call that the U.S. FDA deemed clinical data...
Novartis Sees 15% Global Sales Growth and Significant Investment in China for 2006
Novartis (NYSE: NVS), a multinational pharmaceutical giant, has reported a robust sales revenue of nearly...